Basel, 2005/03/14

Genedata announces the release of a new version of its Genedata Expressionist® computational solution, which focuses on supporting biomarker discovery and in silico prediction. The new release has been developed in close collaboration with discovery and development teams from leading pharmaceutical companies, which have deployed novel biomarker-based strategies in their preclinical research programs.

The software integrates metabolomic, proteomic and transcriptomic data in one platform, leveraging synergies between research teams that collaborate in biomarker discovery and development. Sophisticated mappings have been developed between the different data sources. Biological data analysis and interpretation is supported through extensive functional annotation and the integration of in silico tools for analyzing metabolic and signal transduction pathways. A new tool enables prediction of partial aneuploidy and deletions, information that is highly relevant for specific types of cancer.

Expressionist also features significant expansion of the underlying database system and now covers the entire workflow from sample tracking to analysis and finally, decision support. Together with the possibility of seamlessly integrating proprietary and third party databases, Expressionist represents a scalable and versatile analysis system for biomarker discovery and in-silico prediction of toxicity and treatment compound mode-of-action.

Expressionist's dedication to high throughput analysis is further strengthened by tight integration with different application technologies (e.g. Affymetrix' GCOS) enabling fully automated workflows from data generation to data analysis.

Further, Genedata Expressionist® has been developed with keen awareness of the FDA's 21 CFR Part 11. Genedata will be able to offer a fully validated system to streamline process audits within the customer's environment.

"With the new version of Genedata Expressionist® we indicate our commitment to support biomarker discovery and in-silico prediction processes with state-of-the-art turn-key-applications," says Dr. Othmar Pfannes, CEO of Genedata. "The system empowers researchers to identify and validate biomarkers involving different technological platforms."